CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 20 enrolled
Drug / intervention
Sitagliptin +1 moredrug
Likely dose
Sitagliptin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01093651
NCT01093651Phase 3Completed
CompareCT.gov

A Blinded Randomized Controlled Pilot Immunologic and Virologic Safety Trial of an FDA-approved DPPIV-inhibitor in HIV+ Men and Women

Washington University School of Medicine·interventional·Posted Mar 26, 2010·Updated Feb 17, 2014

In Brief

A Phase 3 clinical trial evaluating Sitagliptin and Placebo for Diabetes and Insulin Resistance. Completed, enrolled 20 participants across 1 site.

Detailed Summary

We will test the safety of a new class of anti-diabetes compounds (DPPIV-inhibitors) in people living with HIV. Future trials will examine efficacy for treating diabetes and reducing cardiovascular disease risk in people living with HIV.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes, Insulin Resistance
CountriesUnited States
CollaboratorsThe Campbell Foundation

Timeline

Phase 3CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 26, 2010
Enrollment StartJun 1, 2010
Primary CompletionJun 1, 2011
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 16.3 years ago

Interventions

Sitagliptindrug

100 mg sitagliptin daily for 4-6 months

Placebodrug

Daily placebo for 4-6 months